We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

116 hedge funds and large institutions have $39.6M invested in Sanofi Contingent Value Rights in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

15% more capital invested

Capital invested by funds: $34.4M → $39.6M (+$5.12M)

6% more funds holding

Funds holding: 109 → 116 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 16

Holders
116
Holders Change
+7
Holders Change %
+6.42%
% of All Funds
3.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
16
Reduced
16
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Brigade Capital Management
New York
+$3.09M
2
NGA
New Generation Advisors
Massachusetts
+$427K
3
BHMP
Bardin Hill Management Partners
New York
+$365K
4
HCM
Highbridge Capital Management
New York
+$260K
5
SCM
Stonehill Capital Management
New York
+$127K

Top Sellers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
-$1.15M
2
DAM
Deltec Asset Management
New York
-$63.3K
3
BCM
Basso Capital Management
Connecticut
-$25.3K
4
TL
TowerView LLC
New York
-$12.7K
5
CL
CSS LLC
Illinois
-$10.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teton Advisors
New York
$108K – – –
Goldman Sachs
27
Goldman Sachs
New York
$106K +$5.3K +20,930 +6%
BCM
28
Basso Capital Management
Connecticut
$47K -$25.3K -100,000 -36%
YCM
29
Yakira Capital Management
Connecticut
$42K – – –
First Eagle Investment Management
30
First Eagle Investment Management
New York
$39K – – –
UBS Group
31
UBS Group
Switzerland
$35K +$2.1K +8,300 +7%
EEG
32
E.E. Geduld
$34K – – –
Bank of America
33
Bank of America
North Carolina
$33K -$657 -2,595 -2%
PC
34
Permanens Capital
New York
$31K – – –
PP
35
Paloma Partners
Connecticut
$27K – – –
Citadel Advisors
36
Citadel Advisors
Florida
$20K +$3.78K +14,913 +25%
IRF
37
IBM Retirement Fund
New York
$19K – – –
GI
38
GAMCO Investors
Connecticut
$17K -$127 -500 -0.8%
Wells Fargo
39
Wells Fargo
California
$16K -$426 -1,683 -3%
JP Morgan Chase
40
JP Morgan Chase
New York
$16K – – –
OCM
41
Osterweis Capital Management
California
$14K – – –
Korea Investment Corp
42
Korea Investment Corp
South Korea
$13K – – –
Commonwealth Equity Services
43
Commonwealth Equity Services
Massachusetts
$12K +$33 +131 +0.3%
ZIG
44
Zuckerman Investment Group
Illinois
$12K +$35 +140 +0.3%
DBG
45
De Burlo Group
Massachusetts
$10K +$10.1K +39,800 New
CHAM
46
Clear Harbor Asset Management
Connecticut
$9K – – –
WHI
47
William Harris Investors
Illinois
$9K – – –
Morgan Stanley
48
Morgan Stanley
New York
$8K +$600 +2,370 +8%
SDWMA
49
Schneider Downs Wealth Management Advisors
Pennsylvania
$7K – – –
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$7K +$6.41K +25,321 New
1
2
3 4

GCVRZ Hedge Fund Activity: Q3 2016 in Review

116 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2016, worth a combined $39.6M — up 15% from $34.4M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new GCVRZ positions and 4 closed out — a net gain of 9 holders — while 16 added to existing stakes and 16 trimmed.

The largest buyer was Brigade Capital Management, opening a new position worth an estimated $3.09M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $1.15M sold.

  • 116 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2016, up from 109 in Q2 2016.
  • Funds reported $39.6M of Sanofi Contingent Value Rights stock for Q3 2016, up 15% quarter-over-quarter.
  • 13 funds opened new Sanofi Contingent Value Rights positions in Q3 2016 and 4 closed out, a net change of +9 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q3 2016 was Brigade Capital Management, an estimated $3.09M added.
  • The largest Sanofi Contingent Value Rights seller in Q3 2016 was Oxford Asset Management, an estimated $1.15M sold.

Based on aggregated 13F filings for Q3 2016.